Clinicopathological significance of non-small cell lung cancer with high prevalence of Oct-4 tumor cells

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Chen, Zhenguang ^a   Wang, Tao ^a   Cai, Lie ^a   Su, Chunhua ^a   Zhong, Beilong ^a   Lei, Yiyan ^a   Xiang, Andy ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Angiogenesis; Non small cell lung cancer; Oct 4; Prognosis; Proliferation

Indexed keywords

KI 67 ANTIGEN; MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 4; VASCULOTROPIN; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DENSITY; FEMALE; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MICROVASCULATURE; MOLECULAR MECHANICS; OVERALL SURVIVAL; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE DIFFERENTIATION; TUMOR CELL; ADENOCARCINOMA; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; VASCULARIZATION;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; OCTAMER TRANSCRIPTION FACTOR-3; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84862776589     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-10     Document Type: Article

References (27)

1. American Society of Clinical Oncology: Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology. Ozols RF, Herbst RS, Colson YL, Gralow J, Bonner J, Curran WJ Jr, Eisenberg BL, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Reaman GH, Sawaya R, Schilsky RL, Schuchter LM, Sweetenham JW, Vahdat LT, Winn RJ, J Clin Oncol 2007 25 146 162 17158528 (Pubitemid 350003060)
2. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. D'Addario G, Felip E, Ann Oncol 2009 20 Suppl 4 68 70 19454467
3. Signalling, cell cycle and pluripotency in embryonic stem cells. Burdon T, Smith A, Savatier P, Trends Cell Biol 2002 12 432 438 10.1016/S0962-8924(02) 02352-8 12220864 (Pubitemid 35239952)
4. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Niwa H, Miyazaki J, Smith AG, Nat Genet 2000 24 372 376 10.1038/74199 10742100 (Pubitemid 30187435)
5. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K, Coghlan L, Tang DG, Oncogene 2006 25 1696 1708 10.1038/sj.onc.1209327 16449977
6. Dissecting Oct3/4-regulated gene networks in embryonic stem cells by expression profiling. Matoba R, Niwa H, Masui S, Ohtsuka S, Carter MG, Sharov AA, Ko MS, PLoS One 2006 1 26 10.1371/journal.pone.0000026 17183653
7. Reprogramming of human somatic cells to pluripotency with defined factors. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW, Daley GQ, Nature 2008 451 141 146 10.1038/nature06534 18157115
8. Synergism with germ line transcription factor Oct-4: viral oncoproteins share the ability to mimic a stem cell-specific activity. Brehm A, Ohbo K, Zwerschke W, Botquin V, Jansen-Dürr P, Schöler HR, Mol Cell Biol 1999 19 2635 2643 10082529 (Pubitemid 29144507)
9. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Gu G, Yuan J, Wills M, Kasper S, Cancer Res 2007 67 4807 4815 10.1158/0008-5472.CAN-06-4608 17510410 (Pubitemid 46910189)
10. Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3are expressed in both seminoma and breast carcinoma. Ezeh UI, Turek PJ, Reijo RA, Clark AT, Cancer 2005 104 2255 2265 10.1002/cncr.21432 16228988 (Pubitemid 41579973)
11. OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. Atlasi Y, Mowla SJ, Ziaee SA, Bahrami AR, Int J Cancer 2007 120 1598 1602 10.1002/ijc.22508 17205510 (Pubitemid 46355399)
12. Long-term proliferation of human embryonic stem cell-derived neuroepithelial cells using defined adherent culture conditions. Shin S, Mitalipova M, Noggle S, Tibbitts D, Venable A, Rao R, Stice SL, Stem Cells 2006 24 125 138 10.1634/stemcells.2004-0150 16100006
13. Octamer 4 small interfering RNA results in cancer stem cell-like cell apoptosis. Hu TS, Liu SR, Breiter DR, Wang F, Tang Y, Sun S, Cancer Res 2008 68 6533 6540 10.1158/0008-5472.CAN-07-6642 18701476
14. Downregulation of transcription factor Oct4 induces an epithelial-to-mesenchymal transition via enhancement of Ca2+ influx in breast cancer cells. Hu J, Qin K, Zhang Y, Gong J, Li N, Lv D, Xiang R, Tan X, Biochem Biophys Res Commun 2011 411 4 786 791 10.1016/j.bbrc.2011.07.025 21798248
15. Oct4 expression in human non-small cell lung cancer: implications for therapeutic intervention. Karoubi G, Gugger M, Schmid R, Dutly A, Interact Cardiovasc Thorac Surg 2009 8 393 397 10.1510/icvts.2008.193995 19126554
16. Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas. Passalidou E, Trivella M, Singh N, Ferguson M, Hu J, Cesario A, Granone P, Nicholson AG, Goldstraw P, Ratcliffe C, Tetlow M, Leigh I, Harris AL, Gatter KC, Pezzella F, Br J Cancer 2002 86 244 249 10.1038/sj.bjc.6600015 11870514 (Pubitemid 34185153)
17. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Pezzella F, Pastorino U, Tagliabue E, Andreola S, Sozzi G, Gasparini G, Menard S, Gatter KC, Harris AL, Fox S, Buyse M, Pilotti S, Pierotti M, Rilke F, Am J Pathol 1997 151 1417 1423 9358768 (Pubitemid 27479772)
18. Sobin LH, Wittekind CH, International Union Against Cancer (UICC) TNM Classification Of Malignant Tumors New York: Wiley-Liss 6 2002 99 103
19. Travis WD, Brambilla E, Muller-Hermelink HK, WHO classification of tumors. Pathology and Genetics. Tumors of lung, pleura, thymus and heart Lyon: IARC Press 2004 9 124
20. Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells. Teng Y, Wang X, Wang Y, Ma D, Biochem Biophys Res Commun 2010 392 373 379 10.1016/j.bbrc.2010.01.028 20074550
21. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Hochedlinger K, Yamada Y, Beard C, Jaenisch R, Cell 2005 121 465 477 10.1016/j.cell.2005.02.018 15882627 (Pubitemid 40692305)
22. Oct-3/4 is a dose-dependent oncogenic fate determinant. Gidekel S, Pizov G, Bergman Y, Pikarsky E, Cancer Cell 2003 4 361 370 10.1016/S1535-6108(03) 00270-8 14667503 (Pubitemid 37491097)
23. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown LF, Detmar M, J Exp Med 2005 201 1089 1099 10.1084/jem.20041896 15809353 (Pubitemid 40524677)
24. The clinical significance of lymphangiogenesis and angiogenesis in non-small cell lung cancer patients. Kadota K, Huang CL, Liu D, Ueno M, Kushida Y, Haba R, Yokomise H, Eur J Cancer 2008 44 1057 1067 10.1016/j.ejca.2008.03.012 18396396
25. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, Hung SC, Chang YL, Tsai ML, Lee YY, Ku HH, Chiou SH, PLoS One 2008 3 2637 10.1371/journal.pone.0002637 18612434
26. OCT4 is superior to CD30 in the diagnosis of metastatic embryonal carcinomas after chemotherapy. Sung MT, Jones TD, Beck SD, Foster RS, Cheng L, Hum Pathol 2006 37 662 667 10.1016/j.humpath.2006.01.019 16733205 (Pubitemid 43956531)
27. "Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management. Glinsky GV, J Clin Oncol 2008 26 2846 2853 10.1200/JCO.2008.17.0266 18539963